|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-6-1
|
|
pubmed:abstractText |
Mass treatment as a means to reducing P. falciparum malaria transmission was used during the first global malaria eradication campaign and is increasingly being considered for current control programmes. We used a previously developed mathematical transmission model to explore both the short and long-term impact of possible mass treatment strategies in different scenarios of endemic transmission. Mass treatment is predicted to provide a longer-term benefit in areas with lower malaria transmission, with reduced transmission levels for at least 2 years after mass treatment is ended in a scenario where the baseline slide-prevalence is 5%, compared to less than one year in a scenario with baseline slide-prevalence at 50%. However, repeated annual mass treatment at 80% coverage could achieve around 25% reduction in infectious bites in moderate-to-high transmission settings if sustained. Using vector control could reduce transmission to levels at which mass treatment has a longer-term impact. In a limited number of settings (which have isolated transmission in small populations of 1000-10,000 with low-to-medium levels of baseline transmission) we find that five closely spaced rounds of mass treatment combined with vector control could make at least temporary elimination a feasible goal. We also estimate the effects of using gametocytocidal treatments such as primaquine and of restricting treatment to parasite-positive individuals. In conclusion, mass treatment needs to be repeated or combined with other interventions for long-term impact in many endemic settings. The benefits of mass treatment need to be carefully weighed against the risks of increasing drug selection pressure.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-10229236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-10681341,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-11075770,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-12164291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-12641911,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-12886804,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-1364857,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-13689019,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-14133988,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-14519583,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-14584381,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-15061279,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-15275132,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-16522834,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-17013431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-17311470,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-17445146,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-18493597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-18613962,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-19190781,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-19198649,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-19228438,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-19529761,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-19588433,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-19622056,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-19747403,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-19848588,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-20126256,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-20175930,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-20194698,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-20497536,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-20637696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-20711482,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-20728060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-7785522,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-8765453,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-8990210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-9103763,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21629651-9920049
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1932-6203
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e20179
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The potential contribution of mass treatment to the control of Plasmodium falciparum malaria.
|
|
pubmed:affiliation |
Department of Infectious Disease Epidemiology, MRC Centre for Outbreak Analysis and Modeling, Imperial College London, London, United Kingdom. l.okell@imperial.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
